Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


Delayed Quote. Delayed Nyse - 09/20 04:10:00 pm
163.81 USD   -0.57%
09/20JOHNSON & JOHNSON : The Janssen Pharmaceutical - RYBREVANT (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
09/20JOHNSON & JOHNSON : Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
09/20JOHNSON & JOHNSON : - New Data on RYBREVANT (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : FDA - Coronavirus Update

08/04/2021 | 10:36am EDT

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:In mid-July, the FDA held a stakeholder call to discuss COVID-19 vaccines, including preliminary reports of Guillain-Barre Syndrome following Janssen (Johnson & Johnson) COVID-19 vaccination.

Acting FDA Commissioner Janet Woodcock, M.D. and the Director of FDA's Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D. were featured speakers. The call can be found on the FDA's YouTube pageExternal Link Disclaimer.

Testing updates

As of today, 398 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 279 molecular tests and sample collection devices, 87 antibody and other immune response tests and 32 antigen tests. There are 53 molecular authorizations and one antibody authorization that can be used with home-collected samples. There is one molecular prescription at-home test, three antigen prescription at-home tests, six antigen over-the-counter (OTC) at-home tests and two molecular OTC at-home tests.

The FDA has authorized 13 antigen tests and eight molecular tests for serial screening programs. The FDA has also authorized 595 revisions to EUA authorizations.

Related Information

COVID-19 Vaccines

Coronavirus Disease 2019 (COVID-19)

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


Tel: (1-888-463-6332)

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
09/20JOHNSON & JOHNSON : The Janssen Pharmaceutical - RYBREVANT (amivantamab-vmjw) Pr..
09/20JOHNSON & JOHNSON : Janssen Presents Results from Phase 1b/2 NORSE Study in Pati..
09/20JOHNSON & JOHNSON : - New Data on RYBREVANT (amivantamab-vmjw) in Combination wi..
09/20JOHNSON & JOHNSON : Unit Reports Additional Data from Early Stage Trial of Lung ..
09/20MAUNA KEA TECHNOLOGIES : Initiates $15 Million Capital Raise for Two Investors
09/20MAUNA KEA TECHNOLOGIES : Johnson & Johnson Enter Lung Cancer Research Collaborat..
09/19JOHNSON & JOHNSON : Chris Rock says he tested positive for COVID-19
09/19JOHNSON & JOHNSON : Chris Rock says he has COVID-19, urges vaccination
09/19JOHNSON & JOHNSON : RYBREVANT« (amivantamab-vmjw) Provides Higher Activity and L..
09/19JOHNSON & JOHNSON : New Data on RYBREVANT« (amivantamab-vmjw) in Combination wit..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,0x
Yield 2021 2,54%
Capitalization 431 B 431 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,39x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,81 $
Average target price 185,83 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ABBVIE INC.-0.70%190 378